Oneview Healthcare
(ASX:ONE) has announced it has formed a 5-year R&D partnership with The University of Oxford and Oxford University Hospital NHS Foundation Trust.
The partnership will continue research and development on a clinical pathways product.
The catalyst for the R&D tie-up was the success of an earlier pilot into digital pathways for prostate cancer to improve patient outcomes and deliver cost efficiencies to health systems
.
The new research will focus on expanding the technology to include full commercial deployment at Oxford and expansion of scope into other types of cancer.
Oneview Healthcare
(ASX:ONE) was trading around 1.98 % higher this morning at $2.06.
